Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982968 · ClinicalTrials.gov registry record · NA
Treatment of IPF With Laparoscopic Anti-Reflux Surgery
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
NCT01982968 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 58 participants.
The verdict
NCT01982968, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER) will slow the decline of forced vital capacity (FVC) over 48 weeks.
Interventions
- PROCEDURE Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982968
The ClinicalTrials.gov registry entry for NCT01982968 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Surgery is the first listed.
NCT01982968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982968 about?
NCT01982968 is a clinical study titled "Treatment of IPF With Laparoscopic Anti-Reflux Surgery". This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER) will slow the decline of forced vital capacity (FVC) over 48 weeks.
What is the current status of trial NCT01982968?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2013-12. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01982968?
The interventions under investigation include: Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT01982968?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.